Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.48 · Revenue $7.41B · 1 analysts
Est. EPS $0.68 · Revenue $7.89B · 1 analysts
Est. EPS $5.87 · Revenue $27.42B · 1 analysts
Est. EPS $0.61 · Revenue $9.17B · 1 analysts
$3.06 per share
$3.06 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $18.6B | +8.1% | +27.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $79.2M | -26.4% | -2.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +2.6% | -57.0% | -42.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +1.0% | -29.6% | -76.1% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +0.4% | -32.0% | -23.4% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $193.3M | +167.4% | +301.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +1.0% | +162.3% | +257.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 308.9% | +8.8% | -14.9% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.14x | -5.5% | +6.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $3.9B | +1.7% | -6.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 2.11 vs 2.17 | -2.8% | 1.86 vs 1.48 | +25.7% |
| Revenue Surprise | $18.6B vs $20.9B | -11.0% | $6.8B vs $7.4B | -8.4% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Global GP LLC | other: General Partner | Common units representing limited partner interests | A | 5,000 | $42.81 |
| Jun 17, 2026 | Global GP LLC | other: General Partner | Common units representing limited partner interests | A | 5,000 | $43.28 |
| Jun 15, 2026 | Global GP LLC | other: General Partner | Common units representing limited partner interests | A | 5,000 | $46.69 |
| Jun 12, 2026 | Global GP LLC | other: General Partner | Common units representing limited partner interests | A | 5,000 | $46.50 |
| Jun 10, 2026 | Global GP LLC | other: General Partner | Common units representing limited partner interests | A | 5,000 | $50.17 |
Operator: Good day, everyone. And welcome to the Global Partners Second Quarter 26 Financial Results Conference Call. Today's call is being recorded. With us from Global Partners are President and Chief Executive Officer, Mr. Eric S. Slifka Chief Financial Officer, Mr. Gregory Hanson Chief Operating Officer, Mr. Mark A. Romaine and Chief Legal Officer, Ms. Kristin Seabrook. At this time, I would like to turn the call over to Ms. Seabrook for opening remarks. Please go ahead. Kristin Seabrook: Good morning, everyone, and thank you for joining us. Today's call will include forward-looking statements within the meaning of federal security laws including projections and expectations concerning the future financial and operational performance of Global Partners. No assurances can be given that these projections will be attained, that these expectations will be met. Our assumptions and future performance are subject to a wide range of business risks, uncertainties, and factors, including supply and demand, which could cause actual results to differ materially as described in our filings with the Securities and Exchange Commission. Global Partners undertakes no obligation to revise or update any forward-looking statements. Now it is my pleasure to turn the call over to our President and Chief Executive Officer, Eric S. Slifka. Eric? Eric S. Slifka: Thank you, Kristin, and good morning, everyone. We delivered a strong second quarter with each of our operating segments contributing meaningfully and our teams executing at a high level across the business. These results underscore the strength of Global's integrated liquid energy platform and the advantage of operating across products, markets, and customers. That diversification is a competitive strength and allows us to capture value across changing market conditions and generate attractive returns. During the quarter, our gasoline distribution station operations segment benefited from improved fuel margins, while our wholesale and commercial segment also delivered positive year-over-year growth. These results reinforce the resiliency of our model and the value of maintaining a portfolio of assets that can perform across a variety of operating environments. At the core of our business is predictable, delivering steady cash flow regardless of the market. On top of that foundation is our ability to capture additional value when markets are dynamic and we pursue that upside within a disciplined framework that manages our exposures as conditions shift. Against that backdrop, refined product markets remain volatile with geopolitical developments contributing to elevated price swings, increased inventory risk, and tight inventory levels. Turning briefly to our distribution. Last month, our board approved a quarterly cash distribution of $0.78 per common unit or $3.12 on an annualized basis. The distribution will be paid on August 14th to unitholders of record as of August 12th. Now let me turn the call over to …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Eric S. Slifka | President, CEO & Chairman of Global GP LLC | USD 5,920,176 | Male | 1966 | Active |
Mark A. Romaine | Chief Operating Officer | USD 2,641,485 | Male | 1969 | Active |
Gregory Hanson | Chief Financial Officer | USD 1,566,122 | Male | 1978 | Active |
Kristin Seabrook | Chief Legal Officer & Secretary | USD 1,480,806 | Female | 1977 | Active |
Matthew Spencer | Chief Accounting Officer | USD 1,147,585 | Male | 1979 | Active |
Catie Kerns | Chief Strategy & Transformation Officer | — | Female | — | Active |
Philip Segaloff | Senior Associate General Counsel | — | — | — | Active |
Scott Solomon | Senior Vice President of Investor Relations | — | Male | — | Active |
Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

Global Partners NYSE: GLP reported higher second-quarter earnings and cash flow as stronger gasoline margins and favorable market conditions lifted results across its gasoline distribution, wholesale and commercial segments.

Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 obesity drug space and key data catalysts approach. VKTX's lead asset VK2735 is in large Phase 3 VANQUISH trials, but efficacy expectations are high, and prior data is limited to a small, short Phase 2 study. A pivotal Q3 catalyst is the maintenance dosing study for VK2735; results could drive price volatility and influence funding needs amid high cash burn.

Global Partners LP Common Units (GLP) Q2 2026 Earnings Call Transcript

Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D.
